TITLE

Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: a randomized controlled trial

AUTHOR(S)
Forni, Valentina; Bianchi, Giorgia; Ogna, Adam; Salvadé, Igor; Vuistiner, Philippe; Burnier, Michel; Gabutti, Luca
PUB. DATE
August 2013
SOURCE
BMC Nephrology;2013, Vol. 14 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: In a simulation based on a pharmacokinetic model we demonstrated that increasing the erythropoiesis stimulating agents (ESAs) half-life or shortening their administration interval decreases hemoglobin variability. The benefit of reducing the administration interval was however lessened by the variability induced by more frequent dosage adjustments. The purpose of this study was to analyze the reticulocyte and hemoglobin kinetics and variability under different ESAs and administration intervals in a collective of chronic hemodialysis patients. Methods: The study was designed as an open-label, randomized, four-period cross-over investigation, including 30 patients under chronic hemodialysis at the regional hospital of Locarno (Switzerland) in February 2010 and lasting 2 years. Four subcutaneous treatment strategies (C.E.R.A. every 4 weeks Q4W and every 2 weeks Q2W, Darbepoetin alfa Q4W and Q2W) were compared with each other. The mean square successive difference of hemoglobin, reticulocyte count and ESAs dose was used to quantify variability. We distinguished a short- and a long-term variability based respectively on the weekly and monthly successive difference. Results: No difference was found in the mean values of biological parameters (hemoglobin, reticulocytes, and ferritin) between the 4 strategies. ESAs type did not affect hemoglobin and reticulocyte variability, but C.E.R.A induced a more sustained reticulocytes response over time and increased the risk of hemoglobin overshooting (OR 2.7, p = 0.01). Shortening the administration interval lessened the amplitude of reticulocyte count fluctuations but resulted in more frequent ESAs dose adjustments and in amplified reticulocyte and hemoglobin variability. Q2W administration interval was however more favorable in terms of ESAs dose, allowing a 38% C.E.R.A. dose reduction, and no increase of Darbepoetin alfa. Conclusions: The reticulocyte dynamic was a more sensitive marker of time instability of the hemoglobin response under ESAs therapy. The ESAs administration interval had a greater impact on hemoglobin variability than the ESAs type. The more protracted reticulocyte response induced by C.E.R.A. could explain both, the observed higher risk of overshoot and the significant increase in efficacy when shortening its administration interval. Trial registration: ClinicalTrials.gov: NCT01666301
ACCESSION #
89679445

 

Related Articles

  • Foreword. Carrera, Fernando // Nephrology Dialysis Transplantation;2007, Vol. 22 Issue suppl_4, piv1 

    An introduction to the journal is presented in which the editor discusses an article on haemoglobin (Hb) level stability because of erythropoiesis-stimulating agents (ESA), half-life of darbepoetin, and extended dosage of ESAs.

  • DIALYSIS ANAEMIA.  // Nephrology Dialysis Transplantation;May2014, Vol. 29 Issue suppl_3, piii491 

    No abstract available.

  • Pharmacodynamics, Pharmacokinetics, and Tolerability of Intravenous or Subcutaneous GC1113, a Novel Erythropoiesis-Stimulating Agent. Han, HyeKyung; Lee, Jongtae; Shin, Donghoon; Shin, Kwang-Hee; Jeon, Hyewon; Lim, Kyoung; Yoon, Seo; Shin, Sang-Goo; Jang, In-Jin; Cho, Joo-Youn; Yu, Kyung-Sang // Clinical Drug Investigation;Jun2014, Vol. 34 Issue 6, p373 

    Background and Objectives: GC1113, a hybrid Fc-fused erythropoietin, is a novel erythropoiesis-stimulating agent that is expected to have an extended duration of action. The preclinical data showed that the hemoglobin increase lasted longer following GC1113 administration than it did following...

  • Biomedical System Dynamics to Improve Anemia Control With Darbepoetin Alfa in Long-Term Hemodialysis Patients. McCarthy, James T.; Hocum, Craig L.; Albright, Robert C.; Rogers, James; Gallaher, Edward J.; Steensma, David P.; Gudgell, Stephen F.; Bergstralh, Eric. J.; Dillon, John C.; Hickson, LaTonya J.; Williams, Amy W.; Dingli, David // Mayo Clinic Proceedings;Jan2014, Vol. 89 Issue 1, p87 

    Objective: To determine the value of a biomedical system dynamics (BMSD) approach for optimization of anemia management in long-term hemodialysis patients because elevated hemoglobin levels and high doses of erythropoiesis-stimulating agents (ESAs) may negatively affect survival in this...

  • Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data. Carrera, Fernando; Disney, Alex; Molina, Manuel // Nephrology Dialysis Transplantation;2007, Vol. 22 Issue suppl_4, piv19 

    The recombinant human erythropoietins epoetins alfa and beta have relatively short half-lives (∼24 h by subcutaneous route) and have traditionally been administered 2 or 3 times a week for the treatment of anaemia in patients with chronic kidney disease. However, multiple weekly injections...

  • A combined model of human erythropoiesis and granulopoiesis under growth factor and chemotherapy treatment. Schirm, Sibylle; Engel, Christoph; Loeffler, Markus; Scholz, Markus Scholz // Theoretical Biology & Medical Modelling;2014, Vol. 11 Issue 1, p2 

    Background Haematotoxicity of conventional chemotherapies often results in delays of treatment or reduction of chemotherapy dose. To ameliorate these side-effects, patients are routinely treated with blood transfusions or haematopoietic growth factors such as erythropoietin (EPO) or granulocyte...

  • Erythropoiesis stimulating agents: approaches to modulate activity. Sinclair, Angus M. // Biologics: Targets & Therapy;2013, Vol. 7, p161 

    Recombinant human erythropoietin (rHuEPO), such as the approved agents epoetin alfa and epoetin beta, has been used successfully for over 20 years to treat anemia in millions of patients. However, due to the relatively short half-life of the molecule (approximately 8 hours), frequent dosing may...

  • Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability. Arrieta, Javier; Moina, Iñigo; Molina, José; Gallardo, Isabel; Muñiz, María Luisa; Robledo, Carmen; García, Oscar; Vidaur, Fernando; Muñoz, Rosa Inés; Iribar, Izaskun; Aguirre, Román; Maza, Antonio // International Journal of Nephrology & Renovascular Disease;2014, Vol. 7, p353 

    Aim: The objective of the study reported here was to describe dose equivalence and hemoglobin (Hb) stability in a cohort of unselected hemodialysis patients who were switched simultaneously from epoetin alfa to darbepoetin alfa. Methods: This was a multicenter, observational, retrospective study...

  • Impact of C-reactive protein on absolute reticulocyte count in haemodialysis patients: the role of iron status. Mitsopoulos, Efstathios; Tsiatsiou, Maria; Zanos, Stavros; Katodritou, Eirini; Visvardis, Georgios; Papadopoulou, Dorothea; Passadakis, Ploumis; Vargemezis, Vassilis; Tsakiris, Dimitrios // Nephrology Dialysis Transplantation;Mar2011, Vol. 26 Issue 3, p992 

    Background. Τhe exact mechanisms by which the effects of inflammation on erythropoiesis occur are still to be determined. We aimed to examine the relation between C-reactive protein (CRP) and erythropoiesis as quantified by the absolute reticulocyte count (RTC) and the possible effect of iron...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics